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Summary p53 immunostaining was evaluated in cancerous epithelia and adjacent intestinal metaplasia of 135 gastric cancer specimens.
The differential p53 overexpression in different subtypes of intestinal metaplasia and gastric cancer suggests that type liI intestinal metaplasia
is the commonest lesion in dysplasia-carcinoma transition, particularty in the intestinal type of gastric cancer.
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In Correa's model of multistep gastric carcinogenesis (Correa.
1992). intestinal metaplasia (INI) represents the advanced stage of
gastritis that may precede the development of gastric cancer (GC).
The notion that [M is a precancerous condition has been supported
bx epidemiological studies that rexeal a higher risk of dexeloping
GC in patients with IM (Dobrilla et al. 1994). However. IM is not a
homog,eneous condition. It mas be divided into three subtypes
according0 to the differences in enzyme production. mucus content
and presence of paneth cells (Stemmermann. 1994). Various
subtypes of IM have been reported to be associated with different
risks ofGC (Filipe et al. 1994). As accumulation ofgenetic changes
usually underlies the development and progression of tumour
(Fearon et al. 1990). demonstration ofgenetic alterations common
in both metaplastic and neoplastic gastric tissues may provide a
further link between IM and GC. Nexertheless. limited data are
axailable regarding genetic alterations in different subtypes of N1
(Antonioli. 1994: Tahara 1995). To address such an issue. we exal-
uated p53 oxerexpression in cancerous epitheia. adjacent IN and
non-metaplastic epithelia of 135 patients with GC.
PATIENTS AND METHODS
Patients and samples
Samples of sporadic GC x ere obtained from 135 Taiwanese
patients who underuent operation at the National Taiwan
Unix ersity Hospital. Pathological diagnosis was confirmed in
formalin-fixed and haematoxvlin and eosin (H&E)-stained tissue
sections by the same pathologist (CT Shun) and classified
according to histological types (78 intestinal. 57 diffuse types) and
tumour stagying (47 early. 88 adxanced).
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Histopathological determination of intestinal
metaplasia and its subtypes
Specimens from patients were fixed in 10'k buffered formalin.
embedded in paraffin. sectioned and stained with H&E. If IM was
present in H&E staining, a further section was stained usinc hiah-
iron diamine (HID)/alcian blue (AB) technique (Lex. 1965). The
HID/AB stain differentiates acidic mucin into sialomucins (blue)
and sulphomucins (brown-black). Using HID/AB and H&E
staining. the metaplastic lesions were further classified into three
subtypes: type I. complete IM characterized bv resemblingr normal
intestinal epithelium: type II. incomplete INI expressing sialo-
mucins but not sulphomucins: and type HIl. incomplete IM
expressing sulphomucins. If IN expressed more than one subtype
in a gixen sample. such a case was assigned to the least mature
type of metaplasia detected. similarly to the system proposed
prex iouslv (Rugge et al. 1996).
Immunostaining of p53 oncoprotein
This wxas performed by a standard axidin-biotin-peroxidase
complex detection syvstem. Monoclonal antibody DOI (Oncogene
Science. USA) recognizes an epitope betxxeen residues 21 and 25
of human p53 oncoprotein. After the tissue sections x ere
dex axed. microwxaxed and rehy drated. endogenous peroxidase
actixity and non-specific bindines were blocked bx incubation
xith 3%c hydrogen peroxide (H,O,) and non-immune serum
respectively. The slides were then incubated wxith primary mouse
monoclonal antibodies oxernight at 4 C. a biotinyvlated goat anti-
mouse secondanr antibody for 30 min. peroxidase-conjurated
streptax idin for 10 min and finally diaminobenzidine tetrachlor-
ide/HO1 for 10 mn. They xxere then counterstained x ith Maxer's
haematoxylin. Necative control sections wxere prepared by substi-
tuting primary antibodv with buffered saline. and positixe control
sections were obtained from breast carcinomaxwhich is known to
express a hirh lexel of p53 oncoprotein. The percentage of posi-
tixelx stained cells xas exaluated for each tumour section and its
971972 M-S Wu etal
Table 1 p53 overexpression in cancerous lesion, adjacent metaplasia and A
non-rnetaplastic epitelia of patients affected with diffuse and intesinal types
of gastric cancer
Dffuse type (n= 57) Ints*tinay tpe (n = 78)
p53 overexp (+ftd (%) (+)ftsd (%)
Cancerous lesion 20/57 (35.1) 39/78 (50.0)
Earty 4J24 (16.7)-- 1123 (47.8)
Advanced 16/33 (48.5) 28/55 (50.9)
Intestinal metaplasia 0/19 (0)- 24/71 (33.8)
Typel 0/2 (0) 0/4 (0)
Type II 0/7 (0) 2/15 (13.3)
TypelIl 0/10 (0) 22/52 (42.3)
Non-metaplastic epithelia 0/57 (0) 0/78 (0)
'P< 0.01; "P < 0.05 vs intestinal type.
adjacent IM and non-tumorous epithelia. Sections were defined as
immunohistochemically positive when greater than 5% cells
showed distinct nuclear staining.
Statistical analysis
Comparison of such categorical data as incidence ofgenetic alter-
ations between groups was performed by the two-tailed Fisher's
exact or chi-square tests. A P-value less than 0.05 was considered
significant.
RESULTS
Of these 135 patients. 57 were diffuse type and 78 were intestinal
type GC. A significantly higher frequency of IM was noted in
intestinal GC (71i78. 91.0%) than in diffuse GC (19/57. 33.3%:
P < 0.01). The p53 overexpression in cancerous epithelia. adjacent
IM and non-metaplastic epithelia is summarized in Table 1. For
cancerous epithelia. the frequency of p53 overexpression was
significantly lower in the early diffuse GC (4/24. 16.7%) than that
of the early intestinal GC (11/23. 47.8%: P = 0.03). However. no
difference was noted in p53 immunoreactivity between the diffuse
type (16/33. 48.5%) and intestinal type (28/55. 50.9%) of
advanced GC. The intestinal type GC had a higher frequency of
p53 overexpression in their adjacent IM lesions (24/71. 33.8%)
compared with complete absence of p53 overexpression in those
of diffuse type GC (P < 0.01). For different subtypes of IM adja-
cent to the intestinal GC. p53 immunoreactivity was negative in
type 1(0/4) and positive in 13.3% (2/15) oftype II IM and 42.3%
(22/52) of type Ill IM. The positive immunostaining ofp53 in IM
was mainly in the glands of the proliferative zone. which also
showed slight cellular and structural atypia (Figure 1). In contrast.
metaplastic glands without atypia towards the luminal side were
principally negative for p53. Forthe diffuse type GC. no p53 over-
expression was found in adjacent IM irrespective oftheirsubtypes.
No overexpression of p53 oncoprotein was encountered in non-
neoplastic and non-metaplastic foveolar epithelia of both diffuse
and intestinal types ofGC.
DISCUSSION
Ixnreasing evidence indicates that cancerdevelopment is a multistep
event proceeding from normal to preneoplastic lesions to highly
malignant tumours. accompanied by accumulations of multiple
Figure 1 Subtypes of intestnal netapLsia and p53 overexpression by
immunohistochemistry. (A) Type III intestinal metaplasia, characterized by
expressing suffomucin (brown-black color, 200x). (B) p53 overexpression
(positive nuclar staining, arrow) in type III intestinal metaplasia adjacent to
the intestinal type cancer
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genetic alterations (Fearon. 1990). Delineatinc those genes involved
and correlating molecular events with clinicopathological character-
istics may lead to important new insights into the pathogenesis ofGC
(VXright et al. 1992: Tahara. 1995). In this studv. we investicated
whether p53 is a deciding factor for GC. because mutations of p53
represent one of the most common genetic events in tumorigenesis.
Overall. overexpression ofp53 protein. determined bv immunohisto-
chemistry. was observed in 43.7e (59/135) ofGC patients. This falls
Within the previous range of27-57'% irrespective ofstage and histo-
logical subtype (Stemmermann et al. 1994). Intriguingl, we found
that frequency ofp53 overexpression was significantlv lower in early
diffuse GC than in early intestinal GC. but was similar in the diffuse
type and intestinal type ofadvanced GC. This result implies that p53
alteration is an early event in the intestinal type but a late event in the
diffuse type. Similar results have recently been reported by Ranzani
et al ( 1995). Such differences in p53 overexpression. tooether with
divergent clinicopathological and epidemiological features between
diffuse and intestinal GC. support the notion that a distinct molecular
pathway is involved in these two types ofGC (Tahara. 1995).
INT plays a crucial role in the sequential progression from
chronic gastritis. chronic atrophic gastritis. dysplasia to gastric
cancer (Correa. 1992). The observation that IM frequently appears
in the neighbouring epithelium ofdysplasia and GC suggested that
IM is the most common finding in the pathological transition from
dysplasia to carcinoma (Antornoli. 1994). Such a transition into
IM might have been preceded by genetic alterations invisible at a
microscopic level (Gomyo et al. 1996). For example. Tahara et al
(1994) reported that reduction in telomere repeat length and emer-
gence of microsatellite instability occur in a proportion ofcases of
ITM (Semba et al. 1996). A number of reports have shown aberrant
expression of the p53 gene in the development of GC. Without
subtyping of IM. Brito et al (1994) and Shiao et al (1994) have
reported that 0-37.5%;k of IM has p53 alterations. Ochiai et al
(1996) and Gomyo et al ( 1996) further demonstrated that such p53
changes mainly correlate with the incomplete (colonic) type ofIM.
In this studv. we noted there was no nuclear p53 staining in cells of
the nornal castric mucosae. type I IM or the majoritv of type II
ITM. In type III IM. however. p53 overexpression was detected in
42.3c% of intestinal type GC but not in diffuse type GC.
Intrigauingly. all positively stained nuclei of type III IM were
contigluous With the carcinomatous lesion. Collectively. these find-
ings lends support to the multistep progression model of a meta-
plasia-dysplasia cancer sequence. particularly in the intestinal
type GC (Correa. 1992: Rubin. 1997). Furthermore. they also indi-
cate that expression ofp53 oncoprotein can be detected in archival
materials. and. when combined with histopathological diagnosis of
INT. might be used to better predict the GC risk (Caselli. 1996.
Ranzani et al. 1996).
In summarv. our results showing preferential p53 overexpres-
sion in type III IM and early intestinal GC suggested that IM is the
most common lesion in dysplasia-carcinoma transition. particu-
larIv in intestinal type GC.
ABBREVIATIONS
GC. gastric cancer: IM. intestinal metaplasia.
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